MARKET WIRE NEWS

Invesco Small Cap Growth Fund Q1 2025 Commentary

Source: SeekingAlpha

2025-05-11 09:56:00 ET

Summary

  • Both the fund and benchmark index had negative returns for the quarter.
  • We reduced exposure to artificial intelligence (AI)-related stocks, capital markets and cyclical sectors. This strategy has been further reinforced by ongoing tariff uncertainty.
  • We see potential for more volatility through the upcoming season of corporate earnings releases and believe there is increased likelihood of recession.

Standardized performance (%)

as of March 31, 2025

Quarter

YTD

1 Year

3 Years

5 Years

10 Years

Since Inception

Class A shares inception: 10/18/95

NAV

-12.14

-12.14

-7.38

-2.35

9.73

6.20

9.45

Max. Load 5.5%

-16.97

-16.97

-12.47

-4.17

8.49

5.60

9.23

Class R6 shares inception: 09/24/12

NAV

-12.05

-12.05

-7.02

-1.94

10.19

6.68

9.54

Class Y shares inception: 10/03/08

NAV

-12.07

-12.07

-7.13

-2.09

10.00

6.47

10.08

Russell 2000 Growth Index ((USD))

-11.12

-11.12

-4.86

0.78

10.78

6.14

-

Total return ranking vs. Morningstar Small Growth category

(Class A shares at NAV)

-

-

70%

(376 of 549)

76%

(386 of 533)

76%

(372 of 518)

76%

(296 of 393)

-

Read the full article on Seeking Alpha

For further details see:

Invesco Small Cap Growth Fund Q1 2025 Commentary
Vaxcyte Inc.

NASDAQ: PCVX

PCVX Trading

-4.98% G/L:

$56.52 Last:

259,831 Volume:

$58.62 Open:

mwn-alerts Ad 300

PCVX Latest News

PCVX Stock Data

$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App